BMY vs. VRTX: Which Stock Is the Better Value Option?
https://www.zacks.com/stock/news/2322713/bmy-vs-vrtx-which-stock-is-the-better-value-option?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2322713
Aug 15, 2024 - BMY vs. VRTX: Which Stock Is the Better Value Option?
0
Evotec (EVO) Rises 12% on $75M Milestone Payment From BMY
https://www.zacks.com/stock/news/2322158/evotec-evo-rises-12-on-75m-milestone-payment-from-bmy?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2322158
Aug 14, 2024 - A $75 million performance-based and program-based milestone payment has been triggered in favor of Evotec (EVO) under its strategic collaboration with Bristol Myers for molecular glue degraders.
0
Bristol Myers Squibb (BMY) Crossed Above the 200-Day Moving Average: What That Means for Investors
https://www.zacks.com/stock/news/2315178/bristol-myers-squibb-bmy-crossed-above-the-200-day-moving-average-what-that-means-for-investors?cid=CS-ZC-FT-tale_of_the_tape|200_day_moving_average_(yseop)-2315178
Aug 02, 2024 - Is it a good or bad thing when a stock surpasses resistance at the 200-day simple moving average?
0
Biotech Stock Roundup: BMY, GSK, BIIB's Q2 Results, VTVT Down on Setback
https://www.zacks.com/stock/news/2314600/biotech-stock-roundup-bmy-gsk-biib-s-q2-results-vtvt-down-on-setback?cid=CS-ZC-FT-analyst_blog|stock_roundup-2314600
Aug 01, 2024 - Bristol Myers (BMY) and Biogen (BIIB) are in the spotlight following earnings results and regulatory updates, respectively.
0
BMY vs. VRTX: Which Stock Should Value Investors Buy Now?
https://www.zacks.com/stock/news/2312160/bmy-vs-vrtx-which-stock-should-value-investors-buy-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2312160
Jul 30, 2024 - BMY vs. VRTX: Which Stock Is the Better Value Option?
0
Bristol Myers Squibb (BMY) Q2 2024 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2024/07/26/bristol-myers-squibb-bmy-q2-2024-earnings-call-tra/?source=iedfolrf0000001
Jul 26, 2024 - BMY earnings call for the period ending June 30, 2024.
0
Bristol-Myers (BMY) Tops on Q2 Earnings, Ups '24 EPS View
https://www.zacks.com/stock/news/2310144/bristol-myers-bmy-tops-on-q2-earnings-ups-24-eps-view?cid=CS-ZC-FT-analyst_blog|earnings_article-2310144
Jul 26, 2024 - Bristol-Myers (BMY) posts impressive second-quarter results, with both earnings and sales beating their respective estimates. The company also raises its annual earnings guidance.
0
DECK, SKX Higher After Earnings; PCE On Tap Friday
https://www.zacks.com/stock/news/2309545/deck-skx-higher-after-earnings-pce-on-tap-friday?cid=CS-ZC-FT-ahead_of_wall_street-2309545
Jul 25, 2024 - The maker of Hoka footwear, UGG boots and more, posted a giant beat on its fiscal Q1 bottom line.
0
EMA Begins Review of Bristol Myers' (BMY) Opdivo Plus Yervoy for HCC
https://www.zacks.com/stock/news/2306156/ema-begins-review-of-bristol-myers-bmy-opdivo-plus-yervoy-for-hcc?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2306156
Jul 22, 2024 - Bristol Myers' (BMY) application seeking approval for Opdivo, in combination with Yervoy, for the indication of advanced hepatocellular carcinoma gets validation in the EU.
0
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for
https://www.zacks.com/stock/news/2305330/analysts-estimate-bristol-myers-squibb-bmy-to-report-a-decline-in-earnings-what-to-look-out-for?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2305330
Jul 19, 2024 - Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0